Expression rates of 6PGL, 6PGDH, and cytoplasmic NRF2 were relatively low in metastatic breast cancer and primary breast cancer; the mentioned rates were 29.4%, 3.2%, and 10.3% in metastatic breast cancer and 10.7%, 3.6%, and 7.1% in primary breast cancer, respectively. Here, NFE2L2 is linked to breast carcinoma.